Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
NCT05506969Phase 2Completed
- Sponsor
- Dynavax Technologies
- Start
- Aug 2022
- Primary completion
- Oct 2023
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of rF1V vaccine + CpG 1018 in plague, sponsored by Dynavax Technologies. Started Aug 2022; status: completed.
02
Drugs
rF1V vaccine + CpG 1018
03
Conditions
plague
Beyond the preview
Go deeper on NCT05506969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05506969.